Two kinds of hypoglycemic drugs are very effective in colorectal cancer

Share This Post

Obesity is on the rise worldwide and is related to the incidence of colon cancer , but its mechanism has been a mystery. In a new study, Yale University research discovered how obesity drives tumor growth in mice and revealed potential strategies to combat this cancer pathogenesis.

The team studied mice implanted with genetic models of tumors or colon cancer. The researchers first studied the effect of a high-fat diet on mice. Then they gave the mice one of two drugs: one was the controlled release mitochondrial proton mass (CRMP), and the other was metformin (the world’s most commonly used diabetes prescription drug), which burns fat in the liver drug.

The team found that high levels of insulin are the link between obesity and colon cancer. Insulin increases glucose uptake in tumors and  promotes tumor growth. The  researchers also found that both drugs can reduce insulin levels and slow tumor growth in mice.

The researchers say that this study is the first to demonstrate that obesity-induced high insulin levels drive colon cancer by increasing glucose uptake in these models. Although further research is needed to confirm whether these findings are applicable to humans, insulin reduction therapy: metformin, CRMP , And even exercise can help slow or prevent colon cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy